Polaris vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Polaris (6550) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 20, 2026.
As of Aug 20, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Polaris trades at TWD 11.15 versus a fair value of TWD 5.10 (-54%), while Vertex Pharmaceuticals trades at $552 versus $279 (-50%).
Polaris
6550.TW · TWD · Health Care
-54%
upside to fair value
overvalued
PriceTWD 11.15
Fair ValueTWD 5.10
Quality30/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$552
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
PolarisVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
4.87×P/S (TTM)10.06×
0.06×P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
—Dividend yield0.1%
Profitability
0%Net margin36%
—Operating margin38%
-69%Return on equity24%
-21%Return on assets12%
Growth
340%Revenue growth (YoY)8%
84.7%Avg. growth/yr (3Y)10.6%
34.0%Avg. growth/yr (5Y)14.2%
Balance & size
0.40×Debt / equity0.03×
$337MMarket cap$123B
expensiveGrowth qualityhealthy
Polaris leads: 5 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Polarisof which business quality 30 · market factors 19Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
0
72
Quality GrowthAre margins and returns improving?
9
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
67
58
Low VolatilityCalm price path (market factor)
60
85
MomentumPrice trend over the last 3–12 months (market factor)
4
69
52W MomentumDistance to the 52-week high (market factor)
0
90
Net IssuanceBuybacks instead of dilution
59
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Polaris
Asset-BasedTWD 3.97
1 of 1 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
22 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Polaris
Bear TWD 3.51Fair Value TWD 5.10Bull TWD 6.38
TWD 11.15 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$552 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Polaris · Health Care
Quality score30 · bottom 25%
Fair value upside-54% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-50% · below median
Bottom line
As of Aug 20, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Polaris trades at TWD 11.15 versus a fair value of TWD 5.10 (-54%), while Vertex Pharmaceuticals trades at $552 versus $279 (-50%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
